- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of July 30
The Center for Biosimilars® recaps the top 5 articles for the week of July 30, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 30.
Number 5: The Maine legislature has authorized a bill that seeks to combat the misuse of Risk Evaluation and Mitigation Strategy programs within the state.
Number 4: Mylan, together with partner Fujifilm Kyowa Kirin Biologics, has gained a positive opinion on its adalimumab biosimilar from the European Medicines Agency’s Committee for Medicinal Products for Human Use. Mylan plans to sell the drug under the brand name Hulio.
Number 3: England’s National Health Service reports strong savings from biosimilars so far, and says that, this financial year, it could save as much as 100 million pounds, equivalent to 131 million dollars, by using biosimilars.
Number 2: The European Commission has approved Pfizer’s trastuzumab biosimilar, Trazimera, referencing Herceptin, for marketing.
Number 1: Mylan, which in June received FDA approval for its biosimilar pegfilgrastim, Fulphila, has launched the drug in the US marketplace.
Finally, last week, our e-newsletter asked whether eventual marketing of the second filgrastim biosimilar will improve patient access.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
FDA, EMA Approve Second Pair of Denosumab Biosimilars
February 17th 2025The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' denosumab biosimilars, which will be marketed under different names depending on whether they will be used to treat osteoporosis or bone metastases.
